Clinical-stage biotech company targeting RNA modifications for novel cancer therapies.
About
STORM Therapeutics is a clinical-stage biotechnology company focused on developing novel cancer therapies by targeting RNA modifications. Their lead candidate, STC-15, is the first RNA-modifying enzyme inhibitor to enter human clinical trials, specifically inhibiting METTL3, an enzyme crucial for regulating cancer stem cell differentiation. The company aims to reprogram malignant cells and treat diseases, with a current focus on sarcomas and other malignancies.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does STORM Therapeutics do?
STORM Therapeutics is a clinical-stage biotechnology company focused on developing novel cancer therapies by targeting RNA modifications. Their lead candidate, STC-15, is the first RNA-modifying enzyme inhibitor to enter human clinical trials, specifically inhibiting METTL3, an enzyme crucial for regulating cancer stem cell differentiation. The company aims to reprogram malignant cells and treat diseases, with a current focus on sarcomas and other malignancies.
How much funding has STORM Therapeutics raised?
STORM Therapeutics has raised a total of $51M in funding. The most recent round on record is Series C.
Where is STORM Therapeutics headquartered?
STORM Therapeutics is headquartered in Cambridge, England, United Kingdom.
When was STORM Therapeutics founded?
STORM Therapeutics was founded in 2015.
What industry does STORM Therapeutics operate in?
STORM Therapeutics operates in Biotechnology, Pharmaceuticals, Oncology, RNA Therapeutics.
Similar Startups